Lecigon (Entacapone, Levodopa, Carbidopa Monohydrate)

Entacapone blocks the peripheral enzyme COMT, slowing levodopa breakdown. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, preventing levodopa conversion to dopamine outside the brain. Levodopa then crosses the blood‑brain barrier and is converted to dopamine, restoring deficient neurotransmission in the basal ganglia.

The specific dose and dosing schedule of Lecigon are determined by the prescribing physician based on the individual’s disease stage, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Lecigon in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To request Lecigon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lecigon combines a COMT inhibitor (entacapone) with levodopa and carbidopa, offering longer levodopa exposure than levodopa/carbidopa alone. Compared with dopamine agonists, it provides a more physiologic dopamine replacement but may have a higher risk of dyskinesia. Choice of therapy depends on individual symptom patterns, side‑effect tolerance and physician judgment.

Lecigon should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and keep out of reach of children.

Lecigon is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Dosing frequency and timing are individualized by the prescriber to maintain consistent plasma levodopa levels.

Serious risks include severe liver injury, neuroleptic malignant syndrome, anaphylactic reactions, hyperpyrexia, and significant cardiac arrhythmias. Patients should be educated to report symptoms such as jaundice, high fever, muscle rigidity, difficulty breathing, or irregular heartbeat promptly.

Lecigon is contraindicated in patients with known hypersensitivity to any component, those taking non‑selective MAO inhibitors, or individuals with severe hepatic impairment. Caution is also advised for patients with uncontrolled cardiovascular disease, severe renal dysfunction, or a history of neuroleptic malignant syndrome.